Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells

Journal of Neural Transmission

Volumn 119, Issue 6, 2012, Pages 685-691

  Li, Jie ^a   Yang, Junfeng ^a   Zhao, Peng ^a   Li, Shen ^a   Zhang, Renyun ^a   Zhang, Xiaobin ^a   Liu, Dan ^a   Zhang, Benshu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

synuclein; Dopaminergic neuron; Neuromelanin; Oxidative stress; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; FREE RADICAL; HYDROXYL RADICAL; NEUROMELANIN; OXIDIZING AGENT; REAGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL LINE; CELL VIABILITY; CYTOTOXICITY; DOPAMINERGIC ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID PEROXIDATION; LOCUS CERULEUS; MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ALPHA-SYNUCLEIN; APOPTOSIS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; HYDROXYL RADICAL; IN SITU NICK-END LABELING; IRON; LIPID PEROXIDATION; MALE; MELANINS; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION;

EID: 84863466987     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0753-z     Document Type: Article

References (36)

1. Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L (2010) Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 11:41
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
3. Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28:425-433
4. Dawson T, Mandir A, Lee M (2002) Animal models of PD: pieces of the same puzzle? Neuron 35:219-222
5. Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583-2589
6. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66:489-494
7. Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L (2003) Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. Neurochem Int 42:603-606
8. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86:1142-1148
9. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283-2301
10. Gerlach M, Riederer P, Double KL (2008) Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 14(Suppl 2):S185-S188
11. Goedert M, Spillantini MG, Serpell LC, Berriman J, Smith MJ, Jakes R, Crowther RA (2001) From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc Lond B Biol Sci 356:213-227
12. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128:2654-2664
13. Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125:2431-2445
14. Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E (2002) Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stresssignaling pathway in neuronal cells. J Biol Chem 277:11465-11472
15. Hegde ML, Jagannatha Rao KS (2003) Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease. Arch Biochem Biophys 418:169-178
16. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348
17. Jiang H, Wu YC, Nakamura M, Liang Y, Tanaka Y, Holmes S, Dawson VL, Dawson TM, Ross CA, Smith WW (2007) Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiol Aging 28:1709-1717
18. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 59:1080-1089
19. Kholodilov NG, Oo TF, Burke RE (1999) Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. Neurosci Lett 275:105-108
20. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
21. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, Garcia-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernandez-Ruiz J, Gerlach M, Wullner U, Luddens H, Calabresi P, Auburger G, Gispert S (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 5:e11464
22. Lee M, Hyun D, Halliwell B, Jenner P (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76:998-1009
23. Leong SL, Cappai R, Barnham KJ, Pham CL (2009) Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res 34:1838-1846
24. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL (2005) Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 95:599-608
25. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99:10813-10818
26. Moussa CE, Mahmoodian F, Tomita Y, Sidhu A (2008) Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun 365:833-839
27. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2009) Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 41:2015-2024
28. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
29. Schwyn RC, King JS, Fox CA (1970) Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys. Bol Estud Med Biol 26:139-160
30. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9:2683-2689
31. Tribl F, Asan E, Arzberger T, Tatschner T, Langenfeld E, Meyer HE, Bringmann G, Riederer P, Gerlach M, Marcus K (2009) Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol Cell Proteomics 8:1832-1838
32. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D (2001) Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30:1163-1170
33. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276:44284-44296
34. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600-606
35. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173
36. Zecca L, Zucca FA, Costi P, Tampellini D, Gatti A, Gerlach M, Riederer P, Fariello RG, Ito S, Gallorini M and Sulzer D (2003) The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J Neural Transm Suppl 65:145-155